Overview
AI drug design company merged with Recursion in 2024.
Details
Exscientia pioneered AI-designed small molecules entering clinical trials. Now part of Recursion, contributing chemistry AI and a pipeline of AI-designed drugs.
AI drug design company merged with Recursion in 2024. Exscientia pioneered AI-designed small molecules entering clinical trials. Now part of Recursion, contributing chemistry AI and a pipeline of AI-designed drugs.
AI drug design company merged with Recursion in 2024.
Exscientia pioneered AI-designed small molecules entering clinical trials. Now part of Recursion, contributing chemistry AI and a pipeline of AI-designed drugs.